Hypersensitivity reaction to bortezomib or any other components of the formulation like boron, mannitol, etc., is a contraindication. Bortezomib administration should never be via the intrathecal route.

The drug is not recommended for use in women who are pregnant or breastfeeding. There is a definite risk of harm to the fetus if used during pregnancy. If the female is pregnant and has a life-threatening situation, the use of bortezomib requires a thorough discussion with the patient, oncologists, and members of the ethics committee.